Vor Biopharma
Price & Volume
Stats
See moreOpen | $27.41 |
Previous Close | $27.93 |
Day Range | $26.88-$33.16 |
52W Range | $2.62-$65.80 |
Market Cap | $186.3M |
Shares Short | 19M |
Financials
See moreRevenue (12 Mos) | $0 |
Revenue Growth (YoY) | 0% |
Gross Profit (12 Mos) | $0 |
Diluted EPS | -$273.60 |
News
See moreYahoo Finance • 5 days ago
Vor Biopharma trading halted on Thursday, news pending
Yahoo Finance • 6 days ago
Results of China Phase III Clinical Study of Telitacicept for Generalized Myasthenia Gravis Selected for Oral Presentation at 2025 AANEM Annual Meeting
Yahoo Finance • 6 days ago
Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM
Yahoo Finance • 11 days ago
Vor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum
About
CEO | Dr. Jean-Paul Kress M.D. |
CFO | Mr. Sandesh Mahatme L.L.M. |
Address | 100 Cambridgepark Drive, Cambridge, MA, United States, 02140 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 154 |
